Denileukin Diftitox
- Atc Codes:L01XX29
- CAS Codes:173146-27-5
- PHARMGKB ID:173146-27-5
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Greece: Ontak.
North America
USA: Ontak.
Drug combinations
Chemistry
Denileukin Diftitox: C~2560~H~4036~N~678~O~799~S~17~. Mw: 57647,3. N-L-Methionyl-387-L-histidine-388-L-alanine-1-388-toxin (Corynebacterium diphtheriae strain C7)(388→2′) protein with 2-133-interleukin 2 (human clone pTIL2-21a). CAS-173146-27-5 (1997).
Pharmacologic Category
Other Antineoplastic Agents. (ATC-Code: L01XX29).
Mechanism of action
Fusion protein (a combination of amino acid sequences from diphtheria toxin and IL-2) which selectively delivers the cytotoxic activity of diphtheria toxin to targeted cells. It interacts with the high-affinity IL-2 receptor on the surface of malignant cells to inhibit intracellular protein synthesis, rapidly leading to cell death.
Therapeutic use
Treatment of persistent or recurrent cutaneous T-cell lymphoma in patients whose malignant cells express the CD25 component of the IL-2 receptor. Designated an orphan drug by the FDA for use in this condition.
Pregnancy and lactiation implications
Animal reproduction studies not conducted. Should be given to a pregnant woman only if clearly needed. Lactation is contraindicated during therapy (potential risk).
Unlabeled use
Contraindications
Hypersensitivity to denileukin diftitox, diphtheria toxin, IL-2, or any component of the formulation.
Warnings and precautions
Acute hypersensitivity reactions and a flu-like syndrome developed during infusion. May develop immunogenicity. May impair immune function (patients with cutaneous T-cell lymphoma are predisposed to cutaneous infection). Associated with delayed-onset vascular leak syndrome (should be used with caution in preexisting cardiovascular disease and/or low serum albumin concentrations). Visual disturbances may occur. Caution in patients >65 years (higher incidence and greater severity of anorexia, hypotension, anemia, confusion, rash, nausea, and/or vomiting observed).